[go: up one dir, main page]

MX2016002580A - Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. - Google Patents

Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.

Info

Publication number
MX2016002580A
MX2016002580A MX2016002580A MX2016002580A MX2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A
Authority
MX
Mexico
Prior art keywords
inhibitor
combination
treatment
proliferative diseases
cell proliferative
Prior art date
Application number
MX2016002580A
Other languages
English (en)
Inventor
Leslie Harris Jennifer
Li Nanxin
R Smith Timothy
MOSSE Yael
Wood Andrew
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016002580A publication Critical patent/MX2016002580A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende, separadamente o en conjunto (1) un primer agente el cual es un inhibidor de ALK o una sal farmacéuticamente aceptable del mismo y (2) un segundo agente el cual es un inhibidor de CDK o una sal farmacéuticamente aceptable del mismo. La invención se refiere adicionalmente a al uso de tal combinación en el tratamiento o prevención de enfermedades proliferativas.
MX2016002580A 2013-08-28 2014-08-28 Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. MX2016002580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Publications (1)

Publication Number Publication Date
MX2016002580A true MX2016002580A (es) 2016-10-26

Family

ID=51541330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002580A MX2016002580A (es) 2013-08-28 2014-08-28 Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.

Country Status (12)

Country Link
US (2) US20160361314A1 (es)
EP (1) EP3038652B1 (es)
JP (1) JP6479812B2 (es)
KR (1) KR20160047521A (es)
CN (1) CN106029099A (es)
AU (3) AU2014312261A1 (es)
BR (1) BR112016004358A8 (es)
CA (1) CA2922684A1 (es)
ES (1) ES2674361T3 (es)
MX (1) MX2016002580A (es)
RU (1) RU2016110874A (es)
WO (1) WO2015031666A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2017112948A1 (en) * 2015-12-24 2017-06-29 University Of Florida Research Foundation, Inc. Improved aav production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. G1T38 SUPERIOR DOSAGE RATES
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CA3130706A1 (en) * 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
IL293055A (en) 2019-11-18 2022-07-01 Chugai Pharmaceutical Co Ltd Ret kinase inhibitors in combination with cyclin dependent kinase 4 and/or cyclin dependent kinase 6 (cdk4/6) inhibitors for use in treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230117684A1 (en) * 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148427A (en) * 2006-12-08 2013-04-30 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2091918B1 (en) * 2006-12-08 2014-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
GEP20135785B (en) * 2008-08-22 2013-03-11 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
CN102458443A (zh) * 2009-05-13 2012-05-16 北卡罗来纳大学查珀尔希尔分校 细胞周期蛋白依赖性激酶抑制剂及使用方法
CA2800327A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
HRP20150946T1 (hr) * 2011-02-02 2015-10-09 Novartis Ag Postupci uporabe alk-inhibitora

Also Published As

Publication number Publication date
US20180318305A1 (en) 2018-11-08
WO2015031666A1 (en) 2015-03-05
AU2017219093A1 (en) 2017-09-14
JP6479812B2 (ja) 2019-03-06
US20160361314A1 (en) 2016-12-15
AU2014312261A1 (en) 2016-03-10
KR20160047521A (ko) 2016-05-02
CA2922684A1 (en) 2015-03-05
ES2674361T3 (es) 2018-06-29
RU2016110874A3 (es) 2018-06-27
AU2018236813A1 (en) 2018-10-18
RU2016110874A (ru) 2017-10-04
EP3038652B1 (en) 2018-03-21
BR112016004358A8 (pt) 2020-02-11
CN106029099A (zh) 2016-10-12
JP2016529285A (ja) 2016-09-23
EP3038652A1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
ZA201603342B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12016502355B1 (en) Pharmaceutical composition
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
ZA201606320B (en) Human plasma kallikrein inhibitors
IN2015DN01156A (es)
HK1211475A1 (en) Combination therapy
MX2015017964A (es) Inhibidores de bromodominio.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12016502353A1 (en) Pharmaceutical composition
IN2013MU03583A (es)
PH12016502352A1 (en) Pharmaceutical composition
IN2014MN02236A (es)
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX373272B (es) Terapia de combinacion.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.